{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:06:59Z","timestamp":1747188419216,"version":"3.40.5"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Platelet inventory constraints necessitate ABO\u2010incompatible platelet transfusion. Many minimize the hemolytic impact by confirming low titre (LT) donor isohemagglutinins. This process is costly. Pathogen\u2010reduced platelets (PRP) in platelet additive solutions (PAS) will dilute plasma and decrease high\u2010titre isohemagglutinins (HT). We determined the proportion of HT platelets and incompatible transfusions for units suspended in plasma to reassess the need for titres following introduction of PRP\/PAS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design and Methods<\/jats:title><jats:p>Our titre method is manual tube (1:50) dilution of platelet supernatant from apheresis or whole blood derived buffy coat pools suspended in plasma, tested with A1\/B red cells. Testing included 49,058 pooled and 11,738 apheresis platelets over 4\u2009years. The HT proportion, rate of out\u2010of\u2010group transfusions, and hemolytic reactions were determined. The impact of PAS dilution was estimated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Totally 60,796 platelet units were tested. Group O pooled and group B apheresis platelets had HT in 6.6% and 5.7%, respectively. Group A pooled and apheresis platelets included 2% with HT. Approximately 25% of platelets transfused were ABO\u2010incompatible and no hemolytic reactions were reported. Based on the proportions of PAS\u2010E and plasma for PRP platelets, plasma from each donor comprises 11\u2009mL (6% of total volume) vs 20\u2010257\u2009mL in untreated pools. PAS\u2010E will replace and dilute residual plasma by at least 50%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Rare platelet pools may demonstrate HT. PRP platelets with PAS will reduce titres and may abrogate the need for titration. A strategy of group specific transfusion or transfusion of group A PRP platelet transfusions may be a safe alternative.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.17873","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T15:06:20Z","timestamp":1716649580000},"page":"1279-1286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isohemagglutinin titration in pooled and apheresis platelets"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1910-7606","authenticated-orcid":false,"given":"QingYun","family":"Hua","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology University of Alberta  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce W.","family":"Lyon","sequence":"additional","affiliation":[{"name":"Transfusion &amp; Transplantation Medicine Program Alberta Precision Laboratories  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Duke","sequence":"additional","affiliation":[{"name":"Transfusion &amp; Transplantation Medicine Program Alberta Precision Laboratories  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Felske","sequence":"additional","affiliation":[{"name":"Transfusion &amp; Transplantation Medicine Program Alberta Precision Laboratories  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Transfusion &amp; Transplantation Medicine Program Alberta Precision Laboratories  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Holman","sequence":"additional","affiliation":[{"name":"Transfusion &amp; Transplantation Medicine Program Alberta Precision Laboratories  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazala","family":"Radwi","sequence":"additional","affiliation":[{"name":"Transfusion &amp; Transplantation Medicine Program Alberta Precision Laboratories  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davinder","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Transfusion &amp; Transplantation Medicine Program Alberta Precision Laboratories  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwen","family":"Clarke","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology University of Alberta  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Nahirniak","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology University of Alberta  Edmonton Alberta Canada"},{"name":"Transfusion &amp; Transplantation Medicine Program Alberta Precision Laboratories  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"volume-title":"StatPearls","year":"2023","author":"Khan AI","key":"e_1_2_8_2_1"},{"volume-title":"Bloody easy 5.1: blood transfusions, blood alternatives, and transfusion reactions","year":"2022","author":"Callum JL","key":"e_1_2_8_3_1"},{"volume-title":"Clinical guide to transfusion","year":"2023","author":"Gupta A","key":"e_1_2_8_4_1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.915521"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15655"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000135"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15637"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03574.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2009.10.013"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03290.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351230"},{"volume-title":"Standards for blood banks and transfusion services","year":"2020","author":"AABB standards: American Association of Blood Banks","key":"e_1_2_8_13_1"},{"volume-title":"Blood and blood components: National Standard of Canada","year":"2020","author":"CSA Group","key":"e_1_2_8_14_1"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-909-TOPCAP"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13129"},{"volume-title":"Publications to transfusion","year":"2022","author":"Bodnar M","key":"e_1_2_8_17_1"},{"volume-title":"Clinical guide to transfusion","year":"2022","author":"Blais\u2010Normandin I","key":"e_1_2_8_18_1"},{"volume-title":"National Deployment of pathogen\u2010reduced platelets: fifth update","year":"2023","author":"Howe D","key":"e_1_2_8_19_1"},{"volume-title":"Pathogen reduced platelet concentrates addressing apheresis PLatelets psoralen treated. Circular of Information: For the Use of Human Blood","year":"2023","author":"Canadian Blood Services","key":"e_1_2_8_20_1"},{"volume-title":"Non\u2010pathogen reduced platelet concentrates addressing apheresis platelets PAS added. Circular of Information: For the Use of Human Blood","year":"2023","author":"Canadian Blood Services","key":"e_1_2_8_21_1"},{"volume-title":"Pathogen reduced platelet concentrates addressing pooled platelets psoralen treated. Circular of Information: For the Use of Human Blood","year":"2023","author":"Canadian Blood Services","key":"e_1_2_8_22_1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.03.008"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14523"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15138"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.4103\/ajts.AJTS_150_17"},{"key":"e_1_2_8_27_1","unstructured":"Isohemagglutinin titering performed on an automated Solid\u2010phase and hemagglutinin\u2010based analyzer is comparable to results obtained by manual gel testing.https:\/\/onlinelibrary.wiley.com"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12878"},{"volume-title":"Donor platelet titre \u2010 tube. Inventory testing. Transfusion medicine","year":"2022","author":"Alberta Precision Laboratories","key":"e_1_2_8_29_1"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17028"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.17873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T14:07:41Z","timestamp":1723903661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.17873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/trf.17873"],"URL":"https:\/\/doi.org\/10.1111\/trf.17873","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"type":"print","value":"0041-1132"},{"type":"electronic","value":"1537-2995"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"2023-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}